

Signant SmartSignals® Solutions for  
Ovarian Cancer

# DIGITAL SOLUTIONS THAT DELIVER CLEAR ANSWERS

Ovarian cancer often goes undetected until it has reached an advanced stage, at which point it becomes difficult to treat. Researchers are working to develop new and effective therapies for better prognoses, but they need the right tools. Signant Health's SmartSignals® solutions can generate reliable evidence while offering a patient-centric experience.

## IMPLEMENT ONCOLOGY-FOCUSED eCOA RAPIDLY

Capture COA data from anyone at-home or at-site with our flexible eCOA solutions. Setup your study quickly with a comprehensive library of standard designs and pre-validated instruments. Modern app features ensure precision and accuracy when collecting data from patients, caregivers, or clinicians. Leverage our scientific expertise and global project teams to scale your study from phase I to III and beyond.

## GAIN RICHER INSIGHTS

Integrate our eCOA with Actigraph sensors and wearables to stream a continuous, real-time view of each patients' health status directly to the study teams. The objective data on sleep and activity patterns will enable enhanced insights into the post-treatment recovery associated with each treatment cycle.

## SIMPLIFY CONSENT & RECONSENT

Leverage our eConsent solution to help convey complex information about the study and disease to patients. The solution lets patients flag sections they have questions on and checks their comprehension for a truly informed consent. It manages protocol amendments and re-consent process, so that the correct forms are always completed.

## OFFER PATIENTS SUPPORT

Ovarian cancer patients often enroll in clinical trials after trying chemotherapy and surgery, which can leave them feeling exhausted and depressed. Signant's Patient Concierge solution uses interactive multimedia, built-in reminders, and visit information to keep patients motivated throughout the entire study.

## REDUCE ON-SITE VISITS

Our secure and compliant Telemedicine solution replaces on-site visits with convenient video consultations, making it possible for patients around the world to participate. The virtual platform allows study teams to frequently check in and communicate with patients.

## OPTIMIZE SUPPLY MANAGEMENT

Randomization & Trial Supply Management (RTSM) handles the multiple cohorts and complex dosing schedules involved in ovarian cancer research with ease. Its proprietary algorithms intelligently direct the expensive supplies only where they're needed.

Our Signant SmartSignals solution suite was designed specifically to meet the needs of sponsors, sites, and patients.

# SIGNANT'S OVARIAN CANCER EXPERIENCE BY THE NUMBERS



I - III  
PHASES



14  
TRIALS



2.2k  
SITES



7.6k  
PATIENTS



28  
COUNTRIES



36  
LANGUAGES

## DRIVE BETTER RESEARCH OUTCOMES WITH SIGNANT SMARTSIGNALS SOLUTIONS

These solutions can be used individually or integrated together for a seamless, end-to-end digital experience.



eCOA

[LEARN MORE →](#)



RTSM

[LEARN MORE →](#)



eCONSENT

[LEARN MORE →](#)



TELEMEDICINE

[LEARN MORE →](#)




SENSORS &  
WEARABLES

[LEARN MORE →](#)

## DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



[MEET THE EXPERTS →](#)